SCHEMBL10189265

SCHEMBL10189265

COC(=O)c1cc(-c2csnc2-c2cc(C)c3c(c2)OCO3)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 3/20 0.41
MAPT P10636 6/20 0.36
TP53 P04637 3/20 0.36
TSHR P16473 3/20 0.36
HSD17B10 Q99714 3/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ABL1 P00519 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618939 0.93 TARBP2 (0.42) TARBP2MAPTTP53TSHRHSD17B10
SCHEMBL10189266 0.92 TSHR (0.38) TARBP2MAPTTP53TSHRHSD17B10
SCHEMBL10189258 0.85 NPC1 (0.39) MAPTTP53TSHRHSD17B10ALDH1A1
SCHEMBL12339067 0.84 TARBP2 (0.41) TARBP2MAPTTP53TSHRHSD17B10
SCHEMBL618800 0.84 KMT2A (0.41) MAPTTSHRHSD17B10ALDH1A1KMT2A
SCHEMBL10189259 0.84 TUBB4A (0.36) MAPTALDH1A1KMT2ATDP1HPGD
SCHEMBL10189269 0.83 EDNRB (0.34) MAPTALDH1A1KMT2ATDP1HPGD
SCHEMBL10189242 0.81 MAPT (0.40) MAPTHSD17B10ALDH1A1KMT2AHPGD
SCHEMBL10189256 0.81 FYN (0.33) MAPTKMT2ATDP1KDM4ENPC1
SCHEMBL10189263 0.79 CYP2A6 (0.45) POLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 TARBP2 2656/4885MAPT 95/4885TP53 25/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 TARBP2 2656/4885MAPT 95/4885TP53 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.